At the forefront of therapies for rare and orphan diseasesTM
about us| programs| science & technology | patient advocacy | clinical studies | investors | collaborations | news & events

Home >> Investor Relations >> Investor Relations

Investor Relations

Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the forefront of therapies for rare and orphan diseases. The Company is developing novel, first-in-class treatments for a broad range of human genetic diseases, with a focus on delivering new benefits to individuals with lysosomal storage diseases. Amicus’ lead programs include the small molecule pharmacological chaperones migalastat HCl as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease; and AT2220 (duvoglustat HCl) in combination with ERT for Pompe disease.

View all »Recent Releases

Jan 12, 2015
Amicus Therapeutics Provides Full-Year 2015 Strategic Outlook and Financial Guidance

Jan 8, 2015
Amicus Therapeutics Announces Positive Phase 3 Data on Cardiac Endpoints From Fabry Monotherapy Study 011 and Long Term Extension Study

View all »Events & Presentations

Jan 13, 2015 at 1:30 PM ET
33rd Annual J.P. Morgan Healthcare Conference

Jan 8, 2015 at 7:30 AM ET
Migalastat Monotherapy Phase 3 Cardiac Data

Copyright © 2015 Amicus Therapeutics, Inc. All rights reserved.   Terms of Use | Privacy Policy